RANKL-IN-1
RANKL-IN-1 is a selective and orally active Receptor Activator of Nuclear Factor-κ B Ligand (RANKL) inhibitor with a KD value of 7.6 μM. RANKL-IN-1 exhibits inhibitory activity and selectivity against osteoclastogenesis with an IC50 value of 0.07 μM and SI of 82.57. RANKL-IN-1binds directly to RANKL and blocks the RANKL-induced activation of the NF-κB and MAPK pathways. RANKL-IN-1 can be used for the research of metabolic disease, such as osteoporosis.
For research use only. We do not sell to patients.
- CAS No.: 3108878-05-0
- Formula: C40H55N5O
- Molecular Weight:621.90
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
MMP-9 |
In Vitro
RANKL-IN-1 (Compound 19u) (50-400 nM, 4 days) shows no significant cytotoxicity in RAW264.7 cells[1].
RANKL-IN-1 (50-400 nM, 4 days) inhibits RANKL-induced osteoclastogenesis without affecting osteoblast differentiation in RAW264.7 cells[1].
RANKL-IN-1 (50-400 nM, 4 days) reduces RANKL-induced ROS levels and inhibits bone resorption in RAW264.7 cells[1].
RANKL-IN-1 (50-400 nM, 4 days) inhibits the expression of proteins associated with RANKL-induced osteoclast differentiation in RAW264.7 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:RAW264.7 cells
-
Concentration:50, 100, 200 and 400 nM
-
Incubation Time:4 days
-
Result:Decreased the size of the F-actin ring.
Reduced ROS levels.
-
Cell Line:RAW264.7 cells
-
Concentration:50, 100, 200 and 400 nM
-
Incubation Time:4 days
-
Result:Downregulated the protein expression of TRAF6 and phosphorylation of p65, p38, ERK and JNK.
Downregulated the activity of the c-Fos/NFATc1 signaling and inhibited the expression of CTSK and MMP-9.
Parmacokinetics
| Species | Dose | Route | AUC0-t | AUC0-∞ | T1/2 | Tmax | Cmax | CL | MRT0-t | MRT0-∞ | F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mice[1] | 10 mg/kg | i.v. | 5.529 mg·h/L | 5.814 mg·h/L | 18.981 h | 0.043 h | 3.012 mg/L | 1.748 L/h/kg | 12.394 h | 16.831 h | / |
| Mice[1] | 20 mg/kg | i.g. | 5.907 mg·h/L | 6.558 mg·h/L | 22.658 h | 6.000 h | 0.232 mg/L | / | 20.522 h | 29.128 h | 56.39 % |
| Rat[1] | 10 mg/kg | i.g. | 0.546 mg·h/L | 1.269 mg·h/L | 40.938 h | 5.600 h | 0.024 mg/L | / | 27.227 h | 61.837 h | 30.33 % |
| Rat[1] | 2 mg/kg | i.v. | 0.808 mg·h/L | 0.837 mg·h/L | 7.656 h | 0.017 h | 0.002 mg/L | 2.435 L/h/kg | 6.837 h | 8.410 h | / |
In Vivo
RANKL-IN-1 (0.5-2 mg/kg, p.o., every 2 days for 11 weeks) prevents systemic bone loss in ovariectomy-induced osteoporosis mice models[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Zebrafish osteoporosis models[1]
-
Dosage:0.313, 0.625 and 1.25 μg/mL
-
Administration:96 h
-
Result:Increased zebrafish skull bone mass.
-
Animal Model:Ovariectomy-induced osteoporosis mice models[1]
-
Dosage:0.5, 1 and 2 mg/kg
-
Administration:Orally administration, every 2 days for 11 weeks
-
Result:Increased the bone mineral density, bone volume fraction, trabecular number and the trabecular thickness.
Reduced the trabecular separation and expanded the marrow cavity and trabecular spacing.
Reduced total cholesterol and triglyceride levels and increased high-density lipoprotein cholesterol levels.
Had no significant changes in ALT, AST and BUN levels.
Chemical Information
-
CAS No. 3108878-05-0
-
Molecular Weight 621.90
-
Formula C40H55N5O
-
SMILES
CC1=C(C2=CC3=NC=CN=C31)C=C[C@@]4(C2=CC[C@@]5([C@@]4(CC[C@@]6([C@H]5C[C@](C(N7CCC(CC7)N8CCNCC8)=O)(CC6)C)C)C)C)C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
-
Osteoclast differentiation from monocyte/macrophage precursors
Osteoclast differentiation is an in vitro induction assay in which monocyte/macrophage-lineage precursors are exposed to macrophage colony-stimulating factor (M-CSF) and receptor activator of NF-κB ligand (RANKL), generating multinucleated osteoclasts that are commonly identified by tartrate-resistant acid phosphatase (TRAP) staining and functionally confirmed by resorption pits on dentin, bone, or mineralized substrates. M-CSF supports survival and expansion of osteoclast precursors, while RANKL binding to RANK drives osteoclast commitment, fusion, maturation, and resorptive function; osteoprotegerin inhibits this pathway by binding RANKL and preventing RANK activation. The main readouts are the number of TRAP-positive multinucleated cells, formation of F-actin rings, and resorbed surface area; TRAP-positive multinucleated cells indicate osteoclast differentiation, whereas pit formation on dentin, bone, or mineralized coating indicates functional bone-resorbing activity.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)